Aura Biosciences, Inc.
AURA evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $763.3M
What it means
What to watch
Prepared research question
What matters most for AURA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AURA
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar (belzupacap sarotalocan) for ocular oncology, with a Phase 3 CoMpass trial fully enrolled and topline data expected in the second half of 2027.
Key risk: Clinical trial uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$763.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 10 clinical trials for Aura Biosciences, Inc..
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar (belzupacap sarotalocan) for ocular oncology, with a Phase 3 CoMpass trial fully enrolled and topline data expected in the second half of 2027.
- Phase 3 CoMpass trial for bel-sar in ocular oncology fully enrolled with 108 patients, exceeding enrollment target [news · 2026-08-11]
- Topline data from the Phase 3 CoMpass trial expected in the second half of 2027 [news · 2026-08-11]
- Cash and equivalents of $67.8M as of 2026-06-30, with expected cash runway into the first half of 2029 [sec · filed 2026-08-11]
- Net loss of -$45.6M for the period ending 2026-06-30 [sec]
- Organizational restructuring and deprioritization of the NMIBC program to focus resources on ocular oncology [news · 2026-08-11]
What works
- Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding target, and on track for topline data in 2H 2027 [news · 2026-08-11]
- Cash runway extended into the first half of 2029, providing a multi-year development horizon [sec · filed 2026-08-11]
- Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety profile [news · 2026-08-11]
What to weigh
- Net loss of -$45.6M as of 2026-06-30, reflecting ongoing R&D investment without product revenue [sec]
- NMIBC program being strategically deprioritized, reducing pipeline diversification [news · 2026-08-11]
- Forward-looking statements caution that actual results may differ materially due to clinical and regulatory uncertainties [sec · filed 2026-08-11]
From the filings
Quoted directly from source documents.
Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target
“Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027”
News · August 11, 2026
Cash runway into first half of 2029
“the Company's expected cash runway into the first half of 2029”
SEC filings · August 11, 2026
Organizational restructuring to focus on ocular oncology
“Organizational restructuring and disciplined capital allocation strategy to align with ocular onc”
News · August 11, 2026
Catalyst timeline
- 2027-12-31 · Phase 3 CoMpass trial topline data — Topline data from the fully enrolled Phase 3 CoMpass trial expected in the second half of 2027.
Risks & what to watch (4)›
Key risks
- Clinical trial uncertainty — Phase 3 results may differ from expectations; forward-looking statements caution about risks and uncertainties [sec · filed 2026-08-11]
- Regulatory risk — FDA may disagree with trial designs despite Special Protocol Agreement [sec · filed 2026-05-04]
- Cash burn rate — Net loss of -$45.6M as of 2026-06-30; cash runway depends on disciplined spending [sec]
- Pipeline concentration — Deprioritization of NMIBC program increases reliance on ocular oncology success [news · 2026-08-11]
What to watch
- Topline data from Phase 3 CoMpass trial expected in 2H 2027 [news · 2026-08-11]
- Cash runway updates in future SEC filings; current guidance into first half of 2029 [sec · filed 2026-08-11]
- Progress of organizational restructuring and its impact on operating expenses [news · 2026-08-11]
Sources: Catalysts · News · SEC filings · Generated October 7, 2026 · How we verify sources →
Run Aura Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aura Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.10 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 4.7%
- Days to cover
- 7.2
- Shares short
- 2,192,556
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AURA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aura Biosciences, Inc.?
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar (belzupacap sarotalocan) for ocular oncology, with a Phase 3 CoMpass trial fully enrolled and topline data expected in the second half of 2027.
Who is the CEO of Aura Biosciences, Inc.?
Ms. Natalie C. Holles is the chief executive officer of Aura Biosciences, Inc. (AURA).
Where is Aura Biosciences, Inc. headquartered?
Aura Biosciences, Inc. (AURA) is headquartered in Boston, MA, United States.
What therapeutic areas does Aura Biosciences, Inc. focus on?
Aura Biosciences, Inc. develops therapies across Oncology, Neurology, Ophthalmology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.